Chastened By Cold-FX Flop, Afexa Plots U.S. Return Via Botanical Drug Path
This article was originally published in The Tan Sheet
Executive Summary
Canadian firm Afexa Life Sciences turns its sights southward again, hoping a strong commitment to clinical research will help its flagship Cold-FX product catch on in the U.S.
You may also be interested in...
Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans
Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.
People In Brief
Schiff Nutrition welcomes Steeves-Kiss
Sales & Earnings In Brief
Watson to push FDA on Mucinex ANDAs